Reprocell Makes Investment in Steminent Biotherapeutics Inc

REPROCELL News

 

August 15, 2017

Investment in Steminent Biotherapeutics Inc., a Pioneer of Regenerative Medicine in Taiwan, Developing a Cell-Based Therapy for the Treatment of Spinocerebellar Ataxia

 

Cell Innovation Partners Limited, of which REPROCELL is a member organization, has invested NTD 62 million (JPY 230 million) in Steminent Biotherapeutics Inc. The Company develops cell therapy products for the treatment of multiple diseases including Spinocerebellar Ataxia and Acute Liver Failure. Steminent is the developer of Stemchymal®, allogeneic adipose tissue derived stem cells from healthy donors, which is the most advanced cell therapy product candidate for the treatment of SCA. With the safety of the treatment already confirmed and potential efficacy observed, Stemchymal is currently in a Phase 2 clinical trial for SCA in Taiwan.  Steminent is developing Stemchymal not only in Taiwan but also in the United States and Japan. In the United States, the Company is currently working to initiate Phase 2 clinical trials for SCA in 2018. In Japan, REPROCELL has partnered with Steminent and is planning to initiate Phase 1/2a clinical trials for SCA in 2018.